Wegovy Cuts Food Noise, Cagrilintide Delivers Significant Weight Loss: Novo Nordisk Unveils New Data at EASD 2025 Clinical Trials Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Cagrilintide: What It Is and How It's Being Studied for Weight Loss Novo Nordisk's share plunges 19.5% post release of weight loss drug CagriSema's trial results Company Business News Novo Nordisk Stock Tumbles on CagriSema Trial Data. Why Investors Have Doubts. Barron's